Neuronal levels and sequence of tau modulate the power of brain rhythms

Melanie Das, Sumihiro Maeda, Bozhong Hu, Gui Qiu Yu, Weikun Guo, Isabel Lopez, Xinxing Yu, Chao Tai, Xin Wang, Lennart Mucke

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Neural network dysfunction may contribute to functional decline and disease progression in neurodegenerative disorders. Diverse lines of evidence suggest that neuronal accumulation of tau promotes network dysfunction and cognitive decline. The A152T-variant of human tau (hTau-A152T) increases the risk of Alzheimer's disease (AD) and several other tauopathies. When overexpressed in neurons of transgenic mice, it causes age-dependent neuronal loss and cognitive decline, as well as non-convulsive epileptic activity, which is also seen in patients with AD. Using intracranial EEG recordings with electrodes implanted over the parietal cortex, we demonstrate that hTau-A152T increases the power of brain oscillations in the 0.5–6 Hz range more than wildtype human tau in transgenic lines with comparable levels of human tau protein in brain, and that genetic ablation of endogenous tau in Mapt−/− mice decreases the power of these oscillations as compared to wildtype controls. Suppression of hTau-A152T production in doxycycline-regulatable transgenic mice reversed their abnormal network activity. Treatment of hTau-A152T mice with the antiepileptic drug levetiracetam also rapidly and persistently reversed their brain dysrhythmia and network hypersynchrony. These findings suggest that both the level and the sequence of tau modulate the power of specific brain oscillations. The potential of EEG spectral changes as a biomarker deserves to be explored in clinical trials of tau-lowering therapeutics. Our results also suggest that levetiracetam treatment is able to counteract tau-dependent neural network dysfunction. Tau reduction and levetiracetam treatment may be of benefit in AD and other conditions associated with brain dysrhythmias and network hypersynchrony.

Original languageEnglish
Pages (from-to)181-188
Number of pages8
JournalNeurobiology of Disease
Volume117
DOIs
Publication statusPublished - 2018 Sep 1

Fingerprint

etiracetam
Brain
Alzheimer Disease
Transgenic Mice
Tauopathies
Parietal Lobe
Implanted Electrodes
Doxycycline
Therapeutics
Neurodegenerative Diseases
Anticonvulsants
Disease Progression
Electroencephalography
Biomarkers
Power (Psychology)
Clinical Trials
Neurons

Keywords

  • A152T
  • Alzheimer's disease
  • Biomarker
  • Brain rhythms
  • EEG
  • Epilepsy
  • Levetiracetam
  • Network dysfunction
  • Oscillations
  • Spectrum
  • Tau

ASJC Scopus subject areas

  • Neurology

Cite this

Neuronal levels and sequence of tau modulate the power of brain rhythms. / Das, Melanie; Maeda, Sumihiro; Hu, Bozhong; Yu, Gui Qiu; Guo, Weikun; Lopez, Isabel; Yu, Xinxing; Tai, Chao; Wang, Xin; Mucke, Lennart.

In: Neurobiology of Disease, Vol. 117, 01.09.2018, p. 181-188.

Research output: Contribution to journalArticle

Das, M, Maeda, S, Hu, B, Yu, GQ, Guo, W, Lopez, I, Yu, X, Tai, C, Wang, X & Mucke, L 2018, 'Neuronal levels and sequence of tau modulate the power of brain rhythms', Neurobiology of Disease, vol. 117, pp. 181-188. https://doi.org/10.1016/j.nbd.2018.05.020
Das, Melanie ; Maeda, Sumihiro ; Hu, Bozhong ; Yu, Gui Qiu ; Guo, Weikun ; Lopez, Isabel ; Yu, Xinxing ; Tai, Chao ; Wang, Xin ; Mucke, Lennart. / Neuronal levels and sequence of tau modulate the power of brain rhythms. In: Neurobiology of Disease. 2018 ; Vol. 117. pp. 181-188.
@article{5341dfcb73c1415fbb797eccd987f071,
title = "Neuronal levels and sequence of tau modulate the power of brain rhythms",
abstract = "Neural network dysfunction may contribute to functional decline and disease progression in neurodegenerative disorders. Diverse lines of evidence suggest that neuronal accumulation of tau promotes network dysfunction and cognitive decline. The A152T-variant of human tau (hTau-A152T) increases the risk of Alzheimer's disease (AD) and several other tauopathies. When overexpressed in neurons of transgenic mice, it causes age-dependent neuronal loss and cognitive decline, as well as non-convulsive epileptic activity, which is also seen in patients with AD. Using intracranial EEG recordings with electrodes implanted over the parietal cortex, we demonstrate that hTau-A152T increases the power of brain oscillations in the 0.5–6 Hz range more than wildtype human tau in transgenic lines with comparable levels of human tau protein in brain, and that genetic ablation of endogenous tau in Mapt−/− mice decreases the power of these oscillations as compared to wildtype controls. Suppression of hTau-A152T production in doxycycline-regulatable transgenic mice reversed their abnormal network activity. Treatment of hTau-A152T mice with the antiepileptic drug levetiracetam also rapidly and persistently reversed their brain dysrhythmia and network hypersynchrony. These findings suggest that both the level and the sequence of tau modulate the power of specific brain oscillations. The potential of EEG spectral changes as a biomarker deserves to be explored in clinical trials of tau-lowering therapeutics. Our results also suggest that levetiracetam treatment is able to counteract tau-dependent neural network dysfunction. Tau reduction and levetiracetam treatment may be of benefit in AD and other conditions associated with brain dysrhythmias and network hypersynchrony.",
keywords = "A152T, Alzheimer's disease, Biomarker, Brain rhythms, EEG, Epilepsy, Levetiracetam, Network dysfunction, Oscillations, Spectrum, Tau",
author = "Melanie Das and Sumihiro Maeda and Bozhong Hu and Yu, {Gui Qiu} and Weikun Guo and Isabel Lopez and Xinxing Yu and Chao Tai and Xin Wang and Lennart Mucke",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.nbd.2018.05.020",
language = "English",
volume = "117",
pages = "181--188",
journal = "Neurobiology of Disease",
issn = "0969-9961",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Neuronal levels and sequence of tau modulate the power of brain rhythms

AU - Das, Melanie

AU - Maeda, Sumihiro

AU - Hu, Bozhong

AU - Yu, Gui Qiu

AU - Guo, Weikun

AU - Lopez, Isabel

AU - Yu, Xinxing

AU - Tai, Chao

AU - Wang, Xin

AU - Mucke, Lennart

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Neural network dysfunction may contribute to functional decline and disease progression in neurodegenerative disorders. Diverse lines of evidence suggest that neuronal accumulation of tau promotes network dysfunction and cognitive decline. The A152T-variant of human tau (hTau-A152T) increases the risk of Alzheimer's disease (AD) and several other tauopathies. When overexpressed in neurons of transgenic mice, it causes age-dependent neuronal loss and cognitive decline, as well as non-convulsive epileptic activity, which is also seen in patients with AD. Using intracranial EEG recordings with electrodes implanted over the parietal cortex, we demonstrate that hTau-A152T increases the power of brain oscillations in the 0.5–6 Hz range more than wildtype human tau in transgenic lines with comparable levels of human tau protein in brain, and that genetic ablation of endogenous tau in Mapt−/− mice decreases the power of these oscillations as compared to wildtype controls. Suppression of hTau-A152T production in doxycycline-regulatable transgenic mice reversed their abnormal network activity. Treatment of hTau-A152T mice with the antiepileptic drug levetiracetam also rapidly and persistently reversed their brain dysrhythmia and network hypersynchrony. These findings suggest that both the level and the sequence of tau modulate the power of specific brain oscillations. The potential of EEG spectral changes as a biomarker deserves to be explored in clinical trials of tau-lowering therapeutics. Our results also suggest that levetiracetam treatment is able to counteract tau-dependent neural network dysfunction. Tau reduction and levetiracetam treatment may be of benefit in AD and other conditions associated with brain dysrhythmias and network hypersynchrony.

AB - Neural network dysfunction may contribute to functional decline and disease progression in neurodegenerative disorders. Diverse lines of evidence suggest that neuronal accumulation of tau promotes network dysfunction and cognitive decline. The A152T-variant of human tau (hTau-A152T) increases the risk of Alzheimer's disease (AD) and several other tauopathies. When overexpressed in neurons of transgenic mice, it causes age-dependent neuronal loss and cognitive decline, as well as non-convulsive epileptic activity, which is also seen in patients with AD. Using intracranial EEG recordings with electrodes implanted over the parietal cortex, we demonstrate that hTau-A152T increases the power of brain oscillations in the 0.5–6 Hz range more than wildtype human tau in transgenic lines with comparable levels of human tau protein in brain, and that genetic ablation of endogenous tau in Mapt−/− mice decreases the power of these oscillations as compared to wildtype controls. Suppression of hTau-A152T production in doxycycline-regulatable transgenic mice reversed their abnormal network activity. Treatment of hTau-A152T mice with the antiepileptic drug levetiracetam also rapidly and persistently reversed their brain dysrhythmia and network hypersynchrony. These findings suggest that both the level and the sequence of tau modulate the power of specific brain oscillations. The potential of EEG spectral changes as a biomarker deserves to be explored in clinical trials of tau-lowering therapeutics. Our results also suggest that levetiracetam treatment is able to counteract tau-dependent neural network dysfunction. Tau reduction and levetiracetam treatment may be of benefit in AD and other conditions associated with brain dysrhythmias and network hypersynchrony.

KW - A152T

KW - Alzheimer's disease

KW - Biomarker

KW - Brain rhythms

KW - EEG

KW - Epilepsy

KW - Levetiracetam

KW - Network dysfunction

KW - Oscillations

KW - Spectrum

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=85048790810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048790810&partnerID=8YFLogxK

U2 - 10.1016/j.nbd.2018.05.020

DO - 10.1016/j.nbd.2018.05.020

M3 - Article

C2 - 29859869

AN - SCOPUS:85048790810

VL - 117

SP - 181

EP - 188

JO - Neurobiology of Disease

JF - Neurobiology of Disease

SN - 0969-9961

ER -